Welcome to our dedicated page for Mei Pharma news (Ticker: MEIP), a resource for investors and traders seeking the latest updates and insights on Mei Pharma stock.
The MEIP news page on Stock Titan provides an organized view of public announcements and regulatory disclosures related to MEI Pharma, Inc. and its transition to Lite Strategy, Inc. These items trace the company’s path from a clinical-stage oncology business with a portfolio of cancer drug candidates to an enterprise emphasizing a Litecoin-focused digital asset treasury strategy.
Earlier news releases describe MEI Pharma’s work as a pharmaceutical company with drug candidates such as voruciclib and ME-344, along with updates on cash position, research and development spending, and the evaluation of strategic alternatives. These reports document the company’s efforts to preserve cash, consider out-licensing and merger and acquisition options, and adjust its workforce and clinical programs while seeking to maximize asset value for stockholders.
More recent articles highlight a major strategic shift: the launch of a Litecoin treasury initiative, a large private placement to fund this strategy, and the acquisition of a substantial Litecoin position. The company’s news also details the appointment of digital asset advisors, board changes linked to its treasury focus, and the formal rebranding to Lite Strategy, Inc. with a new NASDAQ ticker symbol, LITS.
Investors and researchers using this page can follow how MEI Pharma’s oncology-focused narrative evolved into a digital asset treasury story, including key milestones such as the private placement, Litecoin acquisitions, and the corporate name and ticker change. For ongoing developments after the symbol transition, users should also review news associated with Lite Strategy, Inc. under its current trading symbol.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
MEI Pharma, Inc. (Nasdaq: MEIP) has announced a 1-for-20 reverse stock split, effective from April 17, 2023. This decision, approved by stockholders on January 5, 2023, aims to increase the per share trading price and meet Nasdaq's minimum bid price requirement for continued listing.
The split will reduce the number of outstanding shares from approximately 133.3 million to around 6.7 million. Fractional shares will not be issued; affected stockholders will receive cash equivalent to their fractional shares based on the closing price on April 14, 2023.
Computershare Trust Company will manage the transfer process. Changes to the CUSIP number will also take effect on the same date.
MEI Pharma and Infinity Pharmaceuticals have announced a merger agreement to create a combined company that will focus on advancing a diverse clinical-stage oncology pipeline. This includes three drug candidates: eganelisib, voruciclib, and ME-344, targeting various cancers. The merger is expected to be an all-stock transaction, with projected cash balance of approximately $100 million to fund operations through mid-2025. MEI shareholders are expected to own 58% and Infinity shareholders 42% of the new entity. The merger seeks to leverage combined expertise and resources to enhance therapeutic options for patients.